N-1,n-1-二甲基-2-(三氟甲基)-1,4-苯二胺 | 54672-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-1,n-1-二甲基-2-(三氟甲基)-1,4-苯二胺
• 英文名称: 4-Dimethylamino-3-trifluormethylanilin
• 英文别名: N1,N1-dimethyl-2-(trifluoromethyl)benzene-1,4-diamine；1-N,1-N-dimethyl-2-(trifluoromethyl)benzene-1,4-diamine
• CAS: 54672-12-7
• 化学式: C₉H₁₁F₃N₂
• mdl: MFCD10686579
• 分子量: 204.195
• InChiKey: ZQEWNTUETRXSRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  N-1,n-1-二甲基-2-(三氟甲基)-1,4-苯二胺 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 生成 N,N-二甲基-2-(三氟甲基)-苯胺
  参考文献：
  名称：

  SubstitutedN,N-Dimethylanilines Containing anortho-Trifluoromethyl Group: a Synthesis ofN,N-Dimethyl-2-trifluoromethylaniline.

  摘要：

  DOI：

  10.1055/s-1974-23461
• 作为产物：
  描述：

  2-二甲氨-5-硝基三氟甲苯 在 palladium on activated charcoal 、 一水合肼 作用下， 以 乙醇 为溶剂， 以80 %的产率得到N-1,n-1-二甲基-2-(三氟甲基)-1,4-苯二胺
  参考文献：
  名称：

  通过三苯胺基聚酰胺的聚合物主链变化调整主要电致变色特性

  摘要：

  成功合成了一种基于三苯胺 (TPA) 的新型二胺，该二胺集成了结构元素，具有高度稳定的氧化还原和电致变色特性，并对其进行了结构表征。通过以下方法获得了三种新的含 TPA 的聚酰胺通过彻底的 NMR 和 FT-IR 研究证实了这种二胺与酰二氯的缩聚反应。主要的电子跃迁和特定的氧化位点分别通过光电和（时间相关的）密度泛函理论（（TD）- DFT）分析进行评估。循环伏安法和光谱电化学研究用于评估氧化还原稳定性，并根据电致变色对比度、响应时间和开关稳定性来理解电致变色行为。因此，合成的聚酰胺综合了高达 67% 的高透射率变化，对着色和热烫的响应时间降至 6.52 s/2.01 s，最大为 219 cm 2/C 的电致变色效率 (EC) 和 500 次循环后衰减高达 5%。所有这些电致变色参数及其变化取决于聚合物中每个酰二氯链段的电子效应。此外，邻位连接甲基的存在降低了整体氧化电位，因此引发了长期稳

  DOI：

  10.1016/j.jphotochem.2022.114272

文献信息

• Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
  申请人：——

  公开号：US20020103203A1

  公开（公告）日：2002-08-01

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  描述了调节和/或抑制特定蛋白激酶活性的酰胺化合物。这些化合物和含有它们的药物组合物能够介导酪氨酸激酶信号传导，以调节和/或抑制不需要的细胞增殖。该发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和牛皮癣的方法。
• Heteroarylphenylurea Derivative
  申请人：Oikawa Nobuhiro

  公开号：US20080119466A1

  公开（公告）日：2008-05-22

  The present invention provides a compound represented by the formula (1): wherein R 1 , R 2 and R 5 are each independently selected from a hydrogen atom, a halogen atom, a C 1 -C 6 alkyl is substituted with a halogen atom and the like; R 3 and R 4 are each independently selected from a hydrogen atom, a halogen atom, a substituted C 1 -C 6 alkyl group and the like; R 6 and R 7 are each independently selected from a hydrogen atom and a halogen atom; Z 1 and Z 2 are each independently selected from a hydrogen atom, a hydroxyl group and —O(CHR 11 )OC(═O)R 12 ; Q is a group of the formula: (wherein G 1 is C—Y 2 or N; a ring A is a benzene ring or a 5- to 6-membered unsaturated heterocycle) a pharmaceutically acceptable salt thereof or a prodrug thereof.

  本发明提供了一种由式（1）表示的化合物：其中，R1、R2和R5分别独立地选自氢原子、卤原子、C1-C6烷基被卤原子等取代基；R3和R4分别独立地选自氢原子、卤原子、取代的C1-C6烷基等基团；R6和R7分别独立地选自氢原子和卤原子；Z1和Z2分别独立地选自氢原子、羟基和—O（CHR11）OC（═O）R12；Q是下式的基团：（其中，G1是C—Y2或N；环A是苯环或5-至6-成员的不饱和杂环）；其药学上可接受的盐或前药。
• 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Fink Anne Cynthia

  公开号：US20070060582A1

  公开（公告）日：2007-03-15

  This invention relates to compounds of the formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

  本发明涉及公式（I）中变量取代基的化合物，所述的化合物可用于治疗由异常MAP激酶信号通路引起的疾病和症状，例如癌症。
• AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：EP1252146A1

  公开（公告）日：2002-10-30
• [EN] AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES<br/>[FR] COMPOSES AMIDES DESTINEES A INHIBER LES PROTEINES KINASES
  申请人：AGOURON PHARMA

  公开号：WO2001053274A1

  公开（公告）日：2001-07-26

  Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.